0001640455-19-000095.txt : 20191226
0001640455-19-000095.hdr.sgml : 20191226
20191226170812
ACCESSION NUMBER: 0001640455-19-000095
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191223
FILED AS OF DATE: 20191226
DATE AS OF CHANGE: 20191226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MURRAY RICHARD /CA/
CENTRAL INDEX KEY: 0001242935
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 191311054
MAIL ADDRESS:
STREET 1: 22643 WOODRIDGE CT
CITY: CUPERTINO
STATE: CA
ZIP: 95014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_157739807365922.xml
FORM 4
X0306
4
2019-12-23
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001242935
MURRAY RICHARD /CA/
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
1
0
0
CEO and President
Common Stock
2019-12-23
4
M
0
40000
0.48
A
134510
D
Common Stock
2019-12-23
4
S
0
40000
8.37
D
94510
D
Stock Option (Right to Buy)
0.48
2019-12-23
4
M
0
40000
0.48
D
2024-06-26
Common Stock
40000.0
785169
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019. The Reporting Person exercised no discretion with respect to these transactions.
Represents the weighted average share price of an aggregate total of 40,000 shares sold in the price range of $8.15 to $8.55 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
25% of the option shares vested and became exercisable on July 14, 2015 and the remainder of the option shares vested and became exercisable in 36 monthly installments thereafter.
/s/ Kim C. Drapkin, Attorney-in-Fact
2019-12-26